Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGFR1/2 peptide vaccine study in progressive schwannoma associated with neurofibromatosis type 2
jRCTs031180184Phase 2Completed
- Start
- Sep 2016
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VEGFR1 peptide vaccine in neurofibromatosis type 2 (NF2) and schwannoma. Primary endpoint: Safety and clinical efficacy of vaccine therapy using VEGFR1 and VEGFR2 peptide for neurofibromatosis type 2 with progressive schwannoma. Started Sep 2016; status: completed.
02
Drugs
VEGFR1 peptide vaccine
03
Conditions
neurofibromatosis type 2 (NF2)schwannoma
Beyond the preview
Go deeper on jRCTs031180184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180184.